RGEN

ANALYST NOTE: REPLIGEN CORPORATION (RGEN) DATE: 2026-06-20 CURRENT PRICE: $132.02

1. Structural Readiness

Aggressive/Pre-Breakout Entry: N/A (Current price is holding above support, but no breakout signal has triggered) Current Price: $132.02 Extension: — (No extension calculated as breakout has not occurred) ATR Current: 4.5% (High) Pivot Strength: — (Pending breakout confirmation)

Analysis of Setup:

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Platforms, Tools & CRO/CDMO (Tier Direct) Confidence: High

Repligen operates as a direct beneficiary of the secular expansion in biologic drug manufacturing. The company provides the essential "platforms and tools" required to produce monoclonal antibodies (mAbs), antibody-drug conjugates, RNA-based therapeutics, and cell and gene therapies. As the market for biologics expands, the demand for the efficiency, flexibility, and yield improvements that Repligen's technologies provide is structural. The company is not merely a passive participant but a critical enabler for large biopharma and CDMOs facing production cost and capacity pressures.

3. Business Overview

Business Model & Industry: Repligen Corporation is a global life sciences company developing and commercializing innovative bioprocessing technologies and systems. The company operates in the Healthcare sector, specifically within the Life Sciences Tools & Services industry. Its business model relies on selling high-margin equipment, consumables, and software that increase efficiencies in the manufacturing of biological drugs.

Key Business Drivers (as of June 2026):

• Portfolio Performance: In Q1 2026, the company delivered $194 million in revenue, driven by healthy demand across all geographies and franchises.
• Segment Growth:
• Analytics: Led growth with over 50% year-over-year growth in Q1 2026, driven by downstream demand and the growing contribution of upstream Analytics offerings.
• Chromatography: Management expects 20%+ growth in 2026.
• Protein: Expected to grow at least low double digits for the year.
• Filtration: Expected to grow mid-single digits on a reported basis in 2026, though this contemplates a moderated Annualized Total Flow (ATF) outlook due to customer-specific timing dynamics expected to be a tailwind in 2027.
• Strategic Acquisitions:
• 908 Devices: Completed acquisition of the desktop PAT (Process Analytical Technology) portfolio on March 4, 2025, expanding capabilities in bioprocessing process analytics.
• Tantti Laboratory: Acquisition of Tantti Laboratory Inc. includes a contingent consideration obligation of up to $54.5 million in cash over a three-year earnout period (Jan 1, 2025 – Dec 31, 2027).
• Restructuring: In Q1 2026, the company initiated restructuring activities to simplify its global manufacturing footprint and align its workforce to support long-term growth.
• Margin Outlook: Management estimates these efficiency efforts should result in at least one point of annualized margin benefit by the end of 2027.
• Guidance: Management reiterated an expectation for 9% to 13% organic growth for 2026, updated to reflect the sale of the non-core, low-margin Polymem business.

4. Archetype and Conviction

Archetype: Growth Leader Fit: The company fits the "Growth Leader" archetype due to its consistent double-digit growth across multiple high-margin franchises (Analytics, Chromatography, Protein) and its strategic positioning in the high-growth biologic manufacturing sector. The sale of the low-margin Polymem business further sharpens the focus on high-quality growth assets.

Conviction Stack:

• Thesis Strength: High. The secular tailwind for biologics and the direct exposure to the "platforms and tools" layer provide a robust macro backdrop.
• Evidence Quality: Strong. Management has provided specific, quantitative guidance for 2026 across all major segments, supported by Q1 2026 results that exceeded expectations in key areas (Analytics +50%).
• Structural Quality: The acquisition of 908 Devices and the restructuring efforts indicate active management of the business to optimize margins and expand the product suite.
• Rerating Potential: Moderate to High. The combination of margin expansion (1 point benefit by end of 2027) and high organic growth (9-13%) suggests potential for multiple expansion if the market continues to reward high-quality biotech infrastructure names.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Continued outperformance in the Analytics and Chromatography segments in subsequent quarters.
• Successful integration of the 908 Devices portfolio leading to accelerated revenue contribution.
• Realization of the margin benefits ahead of the 2027 target.

What Would Invalidate the Case:

• A significant miss on the 9-13% organic growth guidance for 2026.
• A slowdown in the biologic pipeline or a reduction in capital expenditure by large pharma/CDMOs.
• Failure to realize the anticipated margin benefits from restructuring.

Gaps in Evidence:

• Valuation Metrics: No specific P/E, EV/EBITDA, or forward multiple data is available in the evidence block to contextualize the $132.02 price relative to historical or peer valuations.
• Customer Concentration: While the evidence mentions "large pharma" and "emerging biotechs," specific revenue concentration by customer is not detailed.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key evidence: 1) Management reiterated 9-13% organic growth guidance for 2026 with strong Q1 execution (Analytics +50%). 2) Direct exposure to high-growth biologic manufacturing platforms (mAbs, ADCs, RNA) with no major disconfirming evidence. 3) Strategic acquisitions (908 Devices, Tantti) and restructuring efforts positioned to drive margin expansion (1 point benefit by 2027). Expected path: Management expects continued double-digit growth in Analytics and Chromatography, with filtration growth moderating in 2026 before accelerating in 2027. Restructuring efforts should begin contributing to margin expansion by late 2026/2027. Expected horizon: 12 to 18 months for the thesis to fully play out as restructuring benefits and acquisition synergies materialize.